AstraZeneca, FOB Synthesis to Make Bacterial Infection Antibiotic

Jan 29, 2014

Genetic Engineering & Biotechnology News

AstraZeneca and FOB Synthesis will partner to develop a new antibiotic to treat drug-resistant bacterial infections, by potentially combining AZ’s preclinical beta lactamase inhibitor (BLI) with the synthesis company’s preclinical carbapenem antibiotic, designed to help break down bacteria’s resistance to carbapenems. The companies did not disclose the value of their research and development option and license agreement at this time. Read the full story

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments